A Multi-center Phase II Study Evaluating the Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST), Resistent or Intolerant to at Least Imatinib and Sunitinib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 22 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
- 12 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Apr 2017.
- 01 Jul 2016 Results published in the Annals of Oncology